Sound View Wealth Advisors Group LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,236 shares of the company’s stock after selling 669 shares during the period. Johnson & Johnson accounts for about 2.5% of Sound View Wealth Advisors Group LLC’s investment portfolio, making the stock its 3rd largest holding. Sound View Wealth Advisors Group LLC’s holdings in Johnson & Johnson were worth $9,563,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. Newfound Research LLC bought a new stake in Johnson & Johnson during the 3rd quarter valued at about $28,000. Islay Capital Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at about $42,000. FAI Wealth Management increased its stake in Johnson & Johnson by 45.9% during the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock valued at $45,000 after purchasing an additional 101 shares in the last quarter. SeaBridge Investment Advisors LLC increased its stake in Johnson & Johnson by 160.0% during the 2nd quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after purchasing an additional 200 shares in the last quarter. Finally, Crewe Advisors LLC increased its stake in Johnson & Johnson by 909.1% during the 3rd quarter. Crewe Advisors LLC now owns 333 shares of the company’s stock valued at $50,000 after purchasing an additional 300 shares in the last quarter. 67.44% of the stock is owned by institutional investors.
Shares of NYSE JNJ opened at $146.36 on Friday. The firm has a 50 day moving average of $145.51 and a 200 day moving average of $146.57. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $385.30 billion, a price-to-earnings ratio of 23.01, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.22. The company had revenue of $21.08 billion during the quarter, compared to analyst estimates of $20.15 billion. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same period in the previous year, the business posted $2.12 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 7.99 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the transaction, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.27% of the stock is owned by insiders.
A number of analysts have weighed in on JNJ shares. Stifel Nicolaus lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. Raymond James reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Friday. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Cantor Fitzgerald lifted their price target on shares of Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $164.93.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Recommended Story: What is the LIBOR?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.